Greetings, everyone. A spot of rain is falling on the Pharmalot corporate campus this morning, a welcome change from the recent heat. There will, however, be plenty of heat today in Gaithersburg, Maryland, where that FDA panel will vote on the fate of Avandia. Of course, there are other topics of interest, so please join us for a cup of stimulation as we go hunting. Have a nice day...
How Novartis Turned Around Chiron (Xconomy)
Ex-CVS Chief Teams With Wilbur Ross In Healthcare (Associated Press)
10 Firms Expecting Clinical Trial Results (TheStreet)
Blue Cross of Texas Sues Pfizer Over Lyrica Marketing (Southeast Texas Record)
Pfizer Board Sued By Pension Fund Over Marketing Miscues (Bloomberg News)
Lilly To Use Blood Test To Boost Effient Sales (New York Times)
Pfizer To Study Liver Cancer In Korean Patients (GEN)
geese pix thx to auburnxc flickr creative commons
1 Comment
In the words of Marvin Gaye, I heard it through the grapevine that insurance companies by and large will not pay for the Effient blood test. Lilly will have to subsidize this effort if it is to succeed.